Skip to main content
Top
Published in: Journal of Nanoparticle Research 11/2020

01-11-2020 | Research paper

c(RGDyK)-mediated Pluronic-PBCA nanoparticles through the blood-brain barrier to enhance the treatment of central organophosphorus intoxication

Authors: Yuan Liu, Xiaoli Zhou, Xiaofeng Wang, Qian Li, Dongfeng Yin

Published in: Journal of Nanoparticle Research | Issue 11/2020

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Human usually uses oximes as acetylcholinesterase (AChE)-activated antidotes to treat organophosphorus (OP) compound poisoning. In addition, drugs such as atropine can also be used for its detoxification treatment. However, the natural blood-brain barrier (BBB) severely limits the penetration of these drugs into the central nervous system. As a widely used reactivator, HI-6 is difficult to penetrate the BBB due to its hydrophilicity. Therefore, we hope that a large amount of HI-6 can penetrate the BBB through the drug delivery system. They can quickly release and activate the inhibited AChE in the center. Polybutylcyanoacrylate (PBCA) has good biodegradability and biocompatibility, which ensures the safety of the treatment. Pluronic P85 gets the advantages of inhibiting P-glycoprotein (P-gp) efflux and improving drug solubility. In this study, the HI-6-loaded nanoparticles that conjugated with c(RGDyK) cyclic peptide were successfully synthesized, with encapsulation efficiency 63.69%, drug loading 6.2%, average particle size 166.9 nm, and zeta potential − 22.0 mV. The shape was round and evenly distributed. The BBB model was established by astrocytes and brain capillary endothelial cells, and the transendothelial cell resistance values of the BBB model could reach 183 Ω. The penetration effect of the c(RGDyK)-modified nanoparticles was about 4 times the free HI-6 on the BBB model in vitro. The c(RGDyK)-modified nanoparticles were more effective at targeting the brain than the unmodified nanoparticles in vivo. In addition, reactivation evaluation showed that the modified nanoparticles had a higher reactivation rate for poisoned mice, indicating that the nanoparticles modified with c(RGDyK) cyclic peptide had more central targeting. The successful implementation of this study is expected to improve the treatment level of nerve agents.
Graphical abstract

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literature
go back to reference Bi Y, Liu L, Lu Y, Sun T, Shen C, Chen X, Chen Q, An S, He X, Ruan C, Wu Y, Zhang Y, Guo Q, Zheng Z, Liu Y, Lou M, Zhao S, Jiang C (2016) T7 peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces 8:27465–27473. https://doi.org/10.1021/acsami.6b05572CrossRef Bi Y, Liu L, Lu Y, Sun T, Shen C, Chen X, Chen Q, An S, He X, Ruan C, Wu Y, Zhang Y, Guo Q, Zheng Z, Liu Y, Lou M, Zhao S, Jiang C (2016) T7 peptide-functionalized PEG-PLGA micelles loaded with carmustine for targeting therapy of glioma. ACS Appl Mater Interfaces 8:27465–27473. https://​doi.​org/​10.​1021/​acsami.​6b05572CrossRef
go back to reference Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MFM (2010) The GluK1 (GluR5) kainate/ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 336:303–312. https://doi.org/10.1124/jpet.110.171835CrossRef Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MFM (2010) The GluK1 (GluR5) kainate/ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 336:303–312. https://​doi.​org/​10.​1124/​jpet.​110.​171835CrossRef
go back to reference Kuca K, Musilek K, Korabecny J, Karasova J (2013) Influence of the distance between quaternary nitrogen and oxime group on the reactivation ability of oximes -antidotes against nerve agents[J]. J Environ Immunol Toxicol 1:41–43CrossRef Kuca K, Musilek K, Korabecny J, Karasova J (2013) Influence of the distance between quaternary nitrogen and oxime group on the reactivation ability of oximes -antidotes against nerve agents[J]. J Environ Immunol Toxicol 1:41–43CrossRef
go back to reference Miura Y, Takenaka T, Toh K, Wu S, Nishihara H, Kano MR, Ino Y, Nomoto T, Matsumoto Y, Koyama H, Cabral H, Nishiyama N, Kataoka K (2013) Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood–brain tumor barrier. ACS Nano 7:8583–8592. https://doi.org/10.1021/nn402662dCrossRef Miura Y, Takenaka T, Toh K, Wu S, Nishihara H, Kano MR, Ino Y, Nomoto T, Matsumoto Y, Koyama H, Cabral H, Nishiyama N, Kataoka K (2013) Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood–brain tumor barrier. ACS Nano 7:8583–8592. https://​doi.​org/​10.​1021/​nn402662dCrossRef
go back to reference Shawahna R, Decleves X, Scherrmann JM (2013) Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: aspecial focus on transporters and metabolizing enzymes. Curr Drug Metab 14:120–136CrossRef Shawahna R, Decleves X, Scherrmann JM (2013) Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: aspecial focus on transporters and metabolizing enzymes. Curr Drug Metab 14:120–136CrossRef
go back to reference Uchida Y, Ohtsuki S, Terasaki T (2014) Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. Drug Metab Dispos 42:1719–1726. https://doi.org/10.1124/dmd.114.059055CrossRef Uchida Y, Ohtsuki S, Terasaki T (2014) Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. Drug Metab Dispos 42:1719–1726. https://​doi.​org/​10.​1124/​dmd.​114.​059055CrossRef
Metadata
Title
c(RGDyK)-mediated Pluronic-PBCA nanoparticles through the blood-brain barrier to enhance the treatment of central organophosphorus intoxication
Authors
Yuan Liu
Xiaoli Zhou
Xiaofeng Wang
Qian Li
Dongfeng Yin
Publication date
01-11-2020
Publisher
Springer Netherlands
Published in
Journal of Nanoparticle Research / Issue 11/2020
Print ISSN: 1388-0764
Electronic ISSN: 1572-896X
DOI
https://doi.org/10.1007/s11051-020-05039-7

Other articles of this Issue 11/2020

Journal of Nanoparticle Research 11/2020 Go to the issue

Premium Partners